Last reviewed · How we verify
NCT05961137
Orange Park Out-of-Hospital Quality Improvement Study for Improving CMS Sepsis Core Measures
NA trial testing Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol in Sepsis in 66 participants. Completed in 31 August 2022.
31 December 2021
Quick facts
| Lead sponsor | Orange Park Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 66 |
| Start date | 1 April 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 August 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol
- Conventional Prehospital Suspected Sepsis Protocol
Conditions studied
- Sepsis — all drugs for Sepsis →
- Emergency Medical Services — all drugs for Emergency Medical Services →
- Quality Improvement — all drugs for Quality Improvement →
- Shock, Septic — all drugs for Shock, Septic →
Sponsor
Orange Park Medical Center
Who can join
18 and older, any sex, with Sepsis or Emergency Medical Services. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this quality improvement study is to measure the impact of incorporation of a manual rapid fluid infuser (RFI) for intravenous crystalloid infusion in patients with suspected sepsis in the prehospital interval. The main question\[s\] it aims to answer are: * Does the intervention affect the timeliness of fluid administration? * Does the intervention affect CMS sepsis bundle care measure compliance? * Does the intervention affect processes and outcomes of care? * Are there any adverse effects? Researchers will compare this intervention to use of more conventional gravity or pressure-infusion bag crystalloid infusion.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05961137
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other Orange Park Medical Center trials
Trials by the same sponsor.
- NCT06336460 — PENG vs. FIC Blocks in Hip Fractures in the ED · NA · unknown
- NCT05881434 — Influence of a Questionnaire on Patients' Emergency Room Expectations · NA · completed
- NCT03918083 — WILD 5 Wellness: A 30-Day Intervention for Residents · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05961137 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Orange Park Medical Center
- Last refreshed: 27 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05961137.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing